Lecanemab approved for use by US FDA

The US FDA has approved the Alzheimer’s drug lecanemab through the Accelerated Approval pathway. After full data was shared from the Phase III trial at the end of November 2022, the US FDA has approved the use of lecanemab, developed by Eisai (Tokyo, Japan) and Biogen (MA, USA), to treat Alzheimer’s disease in its early stages. The drug is only the second disease-modifying drug to be approved to treat Alzheimer’s. Speaking to the Science Media Centre, John Hardy (University College London; UK) commented: “This is great news and will reset Alzheimer’s research.  Now will come the difficult tasks of ensuring...